Sodium MRI of the Hip

髋关节钠 MRI

• 批准号: 8897271
• 负责人: Guillaume MADELIN
• 金额: $ 8.48万
• 依托单位: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-08-01 至 2017-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8897271
• 关键词: Affect; American; Arthritis; Biochemical; Biochemical Markers; Cartilage; Chemicals; Chronic; Clinical; Coiled Bodies; Collagen Fiber; Complement; Concentration measurement; Cone; Data; Degenerative Disorder; Degenerative polyarthritis; Detection; Development; Diagnosis; Diagnostic Imaging; Diffusion; Diffusion Magnetic Resonance Imaging; Disadvantaged; Disease; Disease Progression; Early Diagnosis; Elderly; Etiology; Future; Gadolinium; Geometry; Glycosaminoglycans; Goals; Gold; Grant; Health; Heterogeneity; Hip Joint; Hip Osteoarthritis; Hip Pain; Hip region structure; Image; Imaging Techniques; Individual; Joints; Liquid substance; Magnetic Resonance Imaging; Maps; Measurement; Measures; Methods; Noise; Nuclear Magnetic Resonance; Pain management; Patients; Performance; Pharmaceutical Preparations; Physiologic pulse; Pilot Projects; Population; Prevalence; Protons; Publishing; Radial; Recovery; Relaxation; Replacement Arthroplasty; Research; Resolution; Risk; Scanning; Sensitivity and Specificity; Signal Transduction; Sodium; Sodium Channel; Speed; Synovial Fluid; Techniques; Time; Tissues; Water; articular cartilage; base; cartilage degradation; data acquisition; disability; follow-up; gadolinium oxide; healthy volunteer; high risk; imaging modality; improved; in vivo; magnetic field; novel; radiofrequency; reconstruction

DESCRIPTION (provided by applicant): Osteoarthritis (OA) is the most common form of arthritis in synovial joints and a leading cause of chronic disability, mainly in the elderly population. It currently affects 9% of the US population and is expected to affect 19% of Americans by 2030. OA is a degenerative disease of articular cartilage and is mainly characterized by a loss of glycosaminoglycans (GAG), change in size and organization of collagen fibers, and increased water content. There is no known cure for OA and present treatments focus mainly on pain management and ultimately, joint replacement. There are many obstacles to studying OA (heterogeneity in etiology, variability in progression of disease, long time periods required to see morphological joint changes), and consequently we currently lack the ability to predict the course of the disease. The limitation of identifying OA patients at riskfor progression and the lack of available non-invasive early biochemical markers have impeded the clinical development of potential disease modifying OA drugs (DMOAD). Specifically, hip osteoarthritis has a prevalence from 3 to 11% in Western population over 35 years old, and it is the main cause of hip pain in older adults. Quantitative sodium magnetic resonance imaging (MRI) is a non-invasive technique that is highly specific to the GAG content in cartilage that could be used to assess the degree of biochemical degradation of cartilage in OA. However, due to the low sodium concentration in vivo, its low sensitivity and fast relaxation, detecting the sodium signal in cartilage requires high fields (>3T), specific coils and specific 3D non-Cartesian sequences with ultrashort echo time. To the best of our knowledge, no study on sodium MRI of the hip was published to date. The recent acquisition of a dual-tuned body coil for imaging at 3T by our research team will allow us to acquire co-registered proton and sodium images of the hip within the same session. Quantitative sodium MRI could therefore provide a unique endogenous assessment of cartilage GAG content in clinically feasible scan times (20-25 min), and allow detection of OA in articular cartilage before morphological damage occurs and help assessing the effect of DMOAD treatments. The aims of this pilot study are: 1) to develop and optimize the acquisition and reconstruction of quantitative sodium MRI of the hip joint in vivo (to optimize the acquisition sequence parameters for minimizing the acquisition time, increasing the signal-to-noise ratio and spatial resolution, to measure relaxation times and B1 maps, and to optimize synovial fluid suppression) and, 2) to apply quantitative sodium MRI to subjects with and without hip OA (to assess repeatability, sensitivity, specificity of the method, with and without fluid suppression). This method could profoundly affect how we diagnose OA in the hip joint and may allow the identification of high risk individuals and also assess DMOAD treatment follow-ups. Successful completion of this pilot project would allow us to apply to a R01 grant for improving the speed of sodium data acquisition (using compressed sensing) and investigating the clinical value of quantitative sodium MRI for assessing different degrees of OA in comparison to other proton-based imaging techniques such as dGEMRIC, T1 mapping or diffusion imaging.

描述（由申请人提供）：骨关节炎（OA）是滑膜关节中关节炎的最常见形式，也是慢性残疾的主要原因，主要是在老年人群中。目前，它影响了美国9％的人口，预计到2030年将影响19％的美国人。OA是关节软骨的退化性疾病，主要是特征的，其特征是糖胺聚糖（GAG）（GAG）（GAG）（GAG），胶原蛋白纤维的大小和组织变化和组织的变化以及增加水含量。没有已知的OA治疗方法，目前的治疗主要集中在疼痛管理上，最终是关节置换。研究OA存在许多障碍（病因的异质性，疾病进展的变异性，看到形态学关节变化所需的长期时间），因此我们目前缺乏预测疾病进程的能力。识别有风险进展的OA患者以及缺乏可用的非侵入性早期生化标记的局限性阻碍了潜在疾病修饰的OA药物（DMOAD）的临床发展。具体而言，髋关节骨关节炎的患病率从35岁以上的西方人口中的3％到11％，这是老年人髋关节疼痛的主要原因。定量钠磁共振成像（MRI）是一种非侵入性技术，对软骨中的GAG含量高度特异，可用于评估OA中软骨的生化降解程度。但是，由于体内钠浓度较低，其敏感性低和快速放松，检测 软骨中的钠信号需要高场（> 3T），特定的线圈和特定的3D非卡牙 超短回声时间的序列。据我们所知，迄今为止，尚无对髋关节钠MRI的研究。我们的研究团队最近收购了一个双音螺旋线圈以在3T处进行成像，这将使我们能够在同一会话中获取髋关节的共同注册的质子和钠图像。因此，定量钠MRI可以在临床上可行的扫描时间（20-25分钟）中对软骨堵嘴含量进行独特的内源评估，并允许在形态损害发生之前检测到关节软骨中的OA，并有助于评估DMOAD处理的作用。这项试验研究的目的是：1）在体内开发和优化对髋关节的定量钠MRI的采集和重建（以优化 acquisition sequence parameters for minimizing the acquisition time, increasing the signal-to-noise ratio and spatial resolution, to measure relaxation times and B1 maps, and to optimize synovial fluid suppression) and, 2) to apply quantitative sodium MRI to subjects with and without hip OA (to assess repeatability, sensitivity, specificity of the method, with and without fluid suppression).这种方法可能会深刻影响我们如何诊断髋关节中的OA，并可以识别高风险个体并评估DMOAD治疗随访。该试点项目的成功完成将使我们能够申请R01赠款，以提高钠数据获取速度（使用压缩感应），并研究定量钠MRI的临床价值，以评估不同程度的OA与其他基于Proton的成像技术（例如Dgemric，T1映射或扩散图像）相比。